Novartis.com | Contact Us | Help | Site Map | Stay Connected | Large Text VersionRegular Text Version

Welcome to Novartis Oncology - The Global Site

 

 

 

Cancer Press Releases at Novartis Oncology

This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room

Press Releases

10-Dec-2009

Further analysis of BIG 1-98 data supports survival advantage for Novartis drug Femara® over tamoxifen in breast cancer patients

Select a year: 2010 | 2009 | 2008 | 2007 | 2006

08-Dec-2009

Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia

 

 

02-Dec-2009

Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting

 

 

25-Nov-2009

Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers

 

 

20-Oct-2009

Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients

 

 

19-Aug-2009

Results in The New England Journal of Medicine confirm Novartis drug Femara® is superior to tamoxifen after breast cancer surgery

 

 

06-Aug-2009

Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy

 

 

24-Jun-2009

Afinitor® and Sandostatin® LAR® Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months

 

 

08-Jun-2009

Afinitor® Phase II data show positive results for patients with multiple types of lymphoma, leading to Phase III trial

 

 

05-Jun-2009

Tasigna® shows rapid and deep responses in newly diagnosed patients with a form of chronic myeloid leukemia

 

 

29-May-2009

Afinitor® recommended for use in the European Union for patients with advanced kidney cancer

 

‹   1-10   11-20   ›  

19 Total results

 

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

 

SEARCH OUR WEBSITES

ABOUT NOVARTIS ONCOLOGY

Learn More About Novartis Oncology

We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.